脓毒症危重患者中持续与间歇给予美罗培南的比较:MERCY随机临床试验
MERCY为双盲随机临床试验,纳入4国26家医院31个ICU中由临床医生处方美罗培南的脓毒症或脓毒性休克危重患者607例,随机接受等剂量美罗培南持续给药(303例)或间歇给药(304例)。主要终点为28天全因死亡与泛耐药或广泛耐药菌出现的复合结局,持续组142例(47%)vs 间歇组149例(49%),相对风险0.96(95%CI 0.81-1.13),P=0.60。4项次要结局均无统计学显著差异;90天死亡率两组均为42%(持续组127/303,间歇组127/304)。未报告与研究药物相关的癫痫发作或过敏反应不良事件。
要点
- 脓毒症危重患者持续输注美罗培南未降低28天死亡与泛耐药/广泛耐药菌出现的复合结局:47% vs 49%,RR 0.96(95%CI 0.81-1.13),P=0.60。
- 90天死亡率持续给药组与间歇给药组均为42%(127/303 vs 127/304)。
- 4项次要终点(含28天无抗生素存活天数、28天无ICU存活天数、90天全因死亡)均无统计学显著差异。
- 未报告与研究药物相关的癫痫发作或过敏反应不良事件;仅记录1例交叉事件。
- 入组患者中61%(369例)为脓毒性休克,从入院到随机化的中位时间为9天(IQR 3-17天),美罗培南中位疗程11天(IQR 6-17天)。
适用人群与场景
- 4国(克罗地亚、意大利、哈萨克斯坦、俄罗斯)26家医院31个ICU中由临床医生处方美罗培南的脓毒症或脓毒性休克危重患者。
- 共607例,平均年龄64岁(SD 15),女性203例(33%),脓毒性休克369例(61%)。
- 从入院到随机化中位时间9天(IQR 3-17天),美罗培南中位疗程11天(IQR 6-17天)。
处置流程与药物剂量
- 等剂量美罗培南经持续给药(n=303)或间歇给药(n=304),具体剂量、给药频次与疗程原文未按方案写明。
研究设计与关键结果
- 双盲随机临床试验,607例脓毒症或脓毒性休克危重患者,持续给药组303例 vs 间歇给药组304例,比较等剂量美罗培南持续与间歇给药。
- 主要终点(28天全因死亡与泛耐药或广泛耐药菌出现的复合结局):持续组142例(47%)vs 间歇组149例(49%),RR 0.96(95%CI 0.81-1.13),P=0.60。
- 4项次要结局(包括28天无抗生素存活天数、28天无ICU存活天数、90天全因死亡)均无统计学显著差异。
- 90天死亡率:持续组42%(127/303)vs 间歇组42%(127/304)。
- 未报告与研究药物相关的癫痫发作或过敏反应不良事件;仅记录1例交叉事件。
- 全部607例纳入28天主要终点测量并完成90天死亡随访。
证据类型、等级与局限
- 证据类型:双盲随机临床试验(MERCY,ClinicalTrials.gov NCT03452839)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在脓毒症或脓毒性休克危重患者中,持续输注美罗培南相比间歇给药未改善28天死亡与泛耐药/广泛耐药菌出现的复合结局,也未改善90天死亡率(两组均为42%),不支持为改善该复合结局而常规改用持续输注。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Meropenem is a widely prescribed β-lactam antibiotic. Meropenem exhibits maximum pharmacodynamic efficacy when given by continuous infusion to deliver constant drug levels above the minimal inhibitory concentration. Compared with intermittent administration, continuous administration of meropenem may improve clinical outcomes.
OBJECTIVE: To determine whether continuous administration of meropenem reduces a composite of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria compared with intermittent administration in critically ill patients with sepsis.
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized clinical trial enrolling critically ill patients with sepsis or septic shock who had been prescribed meropenem by their treating clinicians at 31 intensive care units of 26 hospitals in 4 countries (Croatia, Italy, Kazakhstan, and Russia). Patients were enrolled between June 5, 2018, and August 9, 2022, and the final 90-day follow-up was completed in November 2022.
INTERVENTIONS: Patients were randomized to receive an equal dose of the antibiotic meropenem by either continuous administration (n = 303) or intermittent administration (n = 304).
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28. There were 4 secondary outcomes, including days alive and free from antibiotics at day 28, days alive and free from the intensive care unit at day 28, and all-cause mortality at day 90. Seizures, allergic reactions, and mortality were recorded as adverse events.
RESULTS: All 607 patients (mean age, 64 [SD, 15] years; 203 were women [33%]) were included in the measurement of the 28-day primary outcome and completed the 90-day mortality follow-up. The majority (369 patients, 61%) had septic shock. The median time from hospital admission to randomization was 9 days (IQR, 3-17 days) and the median duration of meropenem therapy was 11 days (IQR, 6-17 days). Only 1 crossover event was recorded. The primary outcome occurred in 142 patients (47%) in the continuous administration group and in 149 patients (49%) in the intermittent administration group (relative risk, 0.96 [95% CI, 0.81-1.13], P = .60). Of the 4 secondary outcomes, none was statistically significant. No adverse events of seizures or allergic reactions related to the study drug were reported. At 90 days, mortality was 42% both in the continuous administration group (127 of 303 patients) and in the intermittent administration group (127 of 304 patients).
CONCLUSIONS AND RELEVANCE: In critically ill patients with sepsis, compared with intermittent administration, the continuous administration of meropenem did not improve the composite outcome of mortality and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03452839.
参考来源
- Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA. 2023. PMID: 37326473. doi:10.1001/jama.2023.10598
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。